Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ALT-803 + m-ceNK cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803||ALT-803 (nogapendekin alfa) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557).|
|m-ceNK cells||Memory Cytokine-Enhanced NK Cells||m-ceNK cells are memory-like natural killer (NK) cells that have increased interferon gamma production in response to stimuli, and may potentially result in tumor growth inhibition (PMID: 27655849).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04898543||Phase I||ALT-803 + m-ceNK cells||QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors||Recruiting||USA||0|